STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
SUTRO BIOPHARMA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.26+0.32 (+2.88%)
Close on Oct 19, 2026
- Market cap
- $186.51M
- P/E (TTM)
- –
- Dividend yield
- –
SUTRO BIOPHARMA, INC. revenue by segment
By business segment
By product or service
| Revenue | Q4 18 | Q3 18 | Q4 17 | Q3 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Collaboration Revenue | $18.43M | $6.92M | $4.04M | $17.50M | 96.6% | +356.2% |
| Other Revenue | $654.00K | $912.00K | $0 | $0 | 3.4% | – |
By region
From the segment and revenue-disaggregation notes of Sutro Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.